Solid Biosciences Aligns with FDA on Phase 3 Trial Design for Duchenne Gene Therapy
Event summary
- Solid Biosciences reached alignment with the FDA on the Phase 3 IMPACT DUCHENNE trial design for SGT-003, a gene therapy for Duchenne muscular dystrophy.
- The trial will be a randomized, double-blind, placebo-controlled study targeting ambulant participants aged 7 to <12 years.
- First participant dosing in the Phase 3 trial is anticipated in Q1 2026.
- 36 participants have been dosed in the ongoing Phase 1/2 INSPIRE DUCHENNE trial, with SGT-003 generally well tolerated as of February 9, 2026.
The big picture
Solid Biosciences' alignment with the FDA on the Phase 3 trial design for SGT-003 marks a critical step in advancing a potential gene therapy for Duchenne muscular dystrophy. The strategic focus on an accelerated approval pathway reflects the company's efforts to navigate the regulatory landscape efficiently. The broader industry context includes intense competition in the gene therapy space, with companies racing to develop effective treatments for rare neuromuscular diseases.
What we're watching
- Regulatory Pathway
- Whether Solid Biosciences can secure a potential accelerated approval pathway for SGT-003 through additional FDA meetings in 1H 2026.
- Trial Execution
- The pace at which Solid Biosciences can initiate and enroll participants in the Phase 3 IMPACT DUCHENNE trial, particularly with potential U.S. site openings.
- Therapeutic Efficacy
- How the confirmatory evidence from the Phase 3 trial will support the long-term viability of SGT-003 as a best-in-class treatment for Duchenne.
Related topics